Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity: Primer.
作者信息
Henriksen Peter A, Rankin Stephen, Lang Ninian N
机构信息
BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.
出版信息
JACC CardioOncol. 2023 Jun 20;5(3):292-297. doi: 10.1016/j.jaccao.2023.05.004. eCollection 2023 Jun.
Abstract
摘要
相似文献
1
Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity: Primer.
JACC CardioOncol. 2023 Jun 20;5(3):292-297. doi: 10.1016/j.jaccao.2023.05.004. eCollection 2023 Jun.
2
Dexrazoxane to Prevent Cardiotoxicity in Adults Treated with Anthracyclines: : CardioOncology Controversies in Cardio-Oncology.
JACC CardioOncol. 2024 Apr 16;6(2):322-324. doi: 10.1016/j.jaccao.2024.02.004. eCollection 2024 Apr.
3
Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity: State-of-the-Art Review.
JACC CardioOncol. 2024 Feb 27;6(2):183-199. doi: 10.1016/j.jaccao.2023.12.009. eCollection 2024 Apr.
4
Preventing Anthracycline-Associated Heart Failure: What Is the Role of Dexrazoxane?: : CardioOncology Controversies in Cardio-Oncology.
JACC CardioOncol. 2024 Feb 13;6(2):318-321. doi: 10.1016/j.jaccao.2024.01.004. eCollection 2024 Apr.
5
Genetics of Anthracycline Cardiomyopathy in Cancer Survivors: State-of-the-Art Review.
JACC CardioOncol. 2020 Nov;2(4):539-552. doi: 10.1016/j.jaccao.2020.09.006. Epub 2020 Dec 22.
6
Potential Applications for Targeted Gene Therapy to Protect Against Anthracycline Cardiotoxicity: Primer.
JACC CardioOncol. 2021 Dec 21;3(5):650-662. doi: 10.1016/j.jaccao.2021.09.008. eCollection 2021 Dec.
7
Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer.
JACC CardioOncol. 2019 Sep 24;1(1):68-79. doi: 10.1016/j.jaccao.2019.08.003. eCollection 2019 Sep.
8
Cardiotoxicity of T-Cell Antineoplastic Therapies: Primer.
JACC CardioOncol. 2022 Dec 20;4(5):616-623. doi: 10.1016/j.jaccao.2022.07.014. eCollection 2022 Dec.
9
Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
J Am Coll Cardiol. 2014 Sep 2;64(9):938-45. doi: 10.1016/j.jacc.2014.06.1167.
10
Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Paediatr Drugs. 2005;7(2):67-76. doi: 10.2165/00148581-200507020-00001.
引用本文的文献
1
PCSK9 Inhibitor Inclisiran Attenuates Cardiotoxicity Induced by Sequential Anthracycline and Trastuzumab Exposure via NLRP3 and MyD88 Pathway Inhibition.
Int J Mol Sci. 2025 Jul 10;26(14):6617. doi: 10.3390/ijms26146617.
2
A systematic review of long-term cardiotoxic effects of treatment in survivors of childhood acute lymphoblastic leukemia.
Mol Cell Pediatr. 2025 Jul 4;12(1):9. doi: 10.1186/s40348-025-00196-y.
3
Risk-guided cardioprotection with carvedilol in patients with breast cancer (CCT guide): a phase 1 randomized clinical trial.
Breast Cancer Res Treat. 2025 Jun;211(2):293-305. doi: 10.1007/s10549-025-07636-3. Epub 2025 Apr 2.
4
Challenges in the implementation of cardio-oncology trials: lessons learnt from investigating statins in the prevention of anthracycline cardiotoxicity.
Cardiooncology. 2024 Dec 18;10(1):88. doi: 10.1186/s40959-024-00292-4.
5
Arterial effects of anthracycline: structural and inflammatory assessments in non-human primates and lymphoma patients.
Clin Sci (Lond). 2025 Jan 15;139(1):29-41. doi: 10.1042/CS20241529.
6
Cardiovascular Considerations Before Cancer Therapy: Gaps in Evidence and Expert Panel Recommendations.
JACC CardioOncol. 2024 Sep 24;6(5):631-654. doi: 10.1016/j.jaccao.2024.07.017. eCollection 2024 Oct.
7
Artificial Intelligence-Enhanced Risk Stratification of Cancer Therapeutics-Related Cardiac Dysfunction Using Electrocardiographic Images.
Circ Cardiovasc Qual Outcomes. 2025 Jan;18(1):e011504. doi: 10.1161/CIRCOUTCOMES.124.011504. Epub 2024 Sep 2.
8
Statins for the Primary Prevention of Anthracycline Cardiotoxicity: A Comprehensive Review.
Curr Oncol Rep. 2024 Oct;26(10):1197-1204. doi: 10.1007/s11912-024-01579-6. Epub 2024 Jul 13.
9
Are Sodium-Glucose Cotransporter-2 Inhibitors the Cherry on Top of Cardio-Oncology Care?
Cardiovasc Drugs Ther. 2024 Jul 3. doi: 10.1007/s10557-024-07604-x.
10
Cardiotoxicity of CPX-351 in children and adolescents with relapsed AML: a Children's Oncology Group report.
Front Cardiovasc Med. 2024 Jun 14;11:1347547. doi: 10.3389/fcvm.2024.1347547. eCollection 2024.
本文引用的文献
1
Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.
Eur Heart J Cardiovasc Pharmacother. 2023 Sep 20;9(6):515-525. doi: 10.1093/ehjcvp/pvad031.
2
Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment.
NEJM Evid. 2022 Sep;1(9). doi: 10.1056/evidoa2200097. Epub 2022 Aug 18.
3
Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.
Cochrane Database Syst Rev. 2022 Sep 27;9(9):CD014638. doi: 10.1002/14651858.CD014638.pub2.
4
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244.
5
Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines.
JACC Heart Fail. 2022 Aug;10(8):559-567. doi: 10.1016/j.jchf.2022.03.006. Epub 2022 Jun 8.
6
Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group.
Cancer. 2022 Feb 15;128(4):788-796. doi: 10.1002/cncr.33974. Epub 2021 Oct 13.
7
Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
Circ Heart Fail. 2021 Nov;14(11):e008209. doi: 10.1161/CIRCHEARTFAILURE.120.008209. Epub 2021 Sep 23.
8
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
Cardiovasc Diabetol. 2021 Jul 23;20(1):150. doi: 10.1186/s12933-021-01346-y.
9
Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol.
Circulation. 2021 Jun 22;143(25):2431-2440. doi: 10.1161/CIRCULATIONAHA.121.054698. Epub 2021 May 16.
10
Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study.
J Am Heart Assoc. 2021 Jan 19;10(2):e018393. doi: 10.1161/JAHA.119.018393. Epub 2021 Jan 6.
Zotero 插件